HC Wainwright restated their hold rating on shares of DENTSPLY SIRONA (NASDAQ:XRAY) in a report published on Thursday. HC Wainwright currently has a $68.00 target price on the medical instruments supplier’s stock.

A number of other brokerages have also commented on XRAY. Stifel Nicolaus raised their price objective on DENTSPLY SIRONA from $66.00 to $70.00 and gave the stock a buy rating in a research report on Monday, November 6th. Zacks Investment Research upgraded DENTSPLY SIRONA from a strong sell rating to a hold rating in a research report on Thursday, October 12th. Robert W. Baird set a $63.00 price objective on DENTSPLY SIRONA and gave the stock a buy rating in a research report on Thursday, October 19th. Cleveland Research lowered DENTSPLY SIRONA from a buy rating to a neutral rating in a research report on Thursday, October 5th. Finally, Barrington Research upgraded DENTSPLY SIRONA from a market perform rating to an outperform rating and set a $73.00 price objective for the company in a research report on Monday, November 6th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $69.15.

Shares of DENTSPLY SIRONA (XRAY) traded down $0.36 on Thursday, reaching $61.95. The company had a trading volume of 2,259,125 shares, compared to its average volume of 1,738,217. The stock has a market cap of $14,228.86, a PE ratio of -17.85, a P/E/G ratio of 2.28 and a beta of 1.31. DENTSPLY SIRONA has a 1 year low of $52.53 and a 1 year high of $68.98. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.32 and a quick ratio of 1.59.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. DENTSPLY SIRONA’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $0.66 EPS. equities analysts anticipate that DENTSPLY SIRONA will post 2.65 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 12th. Shareholders of record on Friday, December 29th were given a dividend of $0.0875 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.35 dividend on an annualized basis and a yield of 0.56%. DENTSPLY SIRONA’s payout ratio is presently -10.09%.

In other news, Director Eric Brandt sold 6,409 shares of DENTSPLY SIRONA stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $68.04, for a total transaction of $436,068.36. Following the completion of the sale, the director now directly owns 12,073 shares in the company, valued at approximately $821,446.92. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mark Thierer purchased 77,000 shares of DENTSPLY SIRONA stock in a transaction dated Monday, November 13th. The shares were purchased at an average price of $66.04 per share, with a total value of $5,085,080.00. The disclosure for this purchase can be found here. Company insiders own 1.99% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. State of Alaska Department of Revenue lifted its holdings in shares of DENTSPLY SIRONA by 73.2% during the 4th quarter. State of Alaska Department of Revenue now owns 31,943 shares of the medical instruments supplier’s stock valued at $2,101,000 after buying an additional 13,500 shares during the last quarter. Frontier Capital Management Co. LLC acquired a new stake in shares of DENTSPLY SIRONA during the 4th quarter valued at about $60,449,000. Oakbrook Investments LLC acquired a new stake in shares of DENTSPLY SIRONA during the 4th quarter valued at about $589,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of DENTSPLY SIRONA by 3.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 795,363 shares of the medical instruments supplier’s stock valued at $52,359,000 after buying an additional 24,585 shares during the last quarter. Finally, Creative Planning lifted its holdings in shares of DENTSPLY SIRONA by 33.8% during the 4th quarter. Creative Planning now owns 14,758 shares of the medical instruments supplier’s stock valued at $971,000 after buying an additional 3,724 shares during the last quarter. Institutional investors and hedge funds own 96.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dailypolitical.com/2018/01/21/dentsply-sirona-xray-stock-rating-reaffirmed-by-hc-wainwright.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.